Net Sales are expected to increase by 5.4 percent Y-o-Y (up 16.5 percent Q-o-Q) to Rs. 1,354.7 crore, according to Emkay.
Net Sales are expected to increase by 25 percent Y-o-Y (up 1 percent Q-o-Q) to Rs. 1,297.4 crore, according to Sharekhan.
Net Sales are expected to increase by 26.1 percent Y-o-Y (up 1.8 percent Q-o-Q) to Rs. 1,308.2 crore, according to ICICI Direct.
Input cost pressure is being increasingly absorbed by companies as the demand environment in weakening
Net Sales are expected to increase by 15 percent Y-o-Y (up 2.9 percent Q-o-Q) to Rs. 1,020 crore, according to HDFC Securities.
Net Sales are expected to increase by 20 percent Y-o-Y (up 7.3 percent Q-o-Q) to Rs. 1,068.2 crore, according to Sharekhan.
Net Sales are expected to increase by 13.7 percent Y-o-Y (up 1.7 percent Q-o-Q) to Rs. 1,012.4 crore, according to ICICI Direct.
Net Sales are expected to increase by 6.7 percent Y-o-Y (up 9.6 percent Q-o-Q) to Rs. 1,140 crore, according to HDFC Securities.
Revenue may decline due to ongoing USFDA import alert and re-inspection in Q2 of Unit 2.
Street will be squarely focused on commentary on 5 observations co received on its unit 2 by USFDA, inspected from Nov 29 to December 6. Analysts expect the observations to turn either into Warning letter or import alert. Unit 2 accounts for around 70 percent of company's revenue.
Divis Laboratories' first quarter profit seen up 9 percent year-on-year to Rs 265.3 crore and revenue may jump 17 percent to Rs 948 crore, according to a CNBC-TV18 poll.
Sales are expected to decrease by 13.7 percent Q-o-Q (up 16.9 percent Y-o-Y) to Rs 945.1 crore, according to Religare Research.
Net Sales are expected to decrease by 15.1 percent Q-o-Q (up 15.0 percent Y-o-Y) to Rs 929.9 crore, according to Edelweiss
Topline growth may be on the back of increased capacity utilisation at new SEZ units and generic business. Analysts feel capacity utilisation rates should rise to 80 percent against 75 percent earlier.
Operating profit in Q3 is likely to jump 28.2 percent to Rs 364 crore and margin may expand 240 basis points to 38.4 percent compared to year-ago period.
Nirmal Bang research expects the companies in their coverage universe to post a 4.4% YoY revenue growth, a 1% decline in EBITDA and a 7.2% fall in net profit. The performance reflects demand slowdown in the economy amid a depreciating Indian rupee.
Sandeep Shenoy of Anand Rathi is bullish on Tech Mahindra and expects the company to perform well ahead. He recommends buying Divis Labs on dips.
Motilal Oswal has come with its March`13 quarterly earning estimates for healthcare sector. The research firm expects a top line growth of 17.4% YoY and EBITDA growth of 21.3% YoY for our pharma universe (excluding one-offs).
Nirmal Bang has come out with its earnings estimates for pharmaceutical sector for the quarter ended December 2012. The research firm feels margins of pharma companies may witness YoY expansion owing to rupee depreciation (6 percent YoY).
Motilal Oswal has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects the topline to grow by 22 percent, EBITDA by 21 percent on the back of strong operational performance by Ranbaxy, Glenmark, Strides, Torrent and Divi's.
Prabhudas Lilladher has come out with its earnings estimates for pharmaceuticals sector for the quarter ended December 2012. The research firm expects top-line growth of 24 percent YoY for its coverage universe (excluding one-offs), with EBITDA growth at a robust 24 percent YoY.
In an interview to CNBC-TV18 Bino Pathiparampil of IIFL shared his expectation from various pharmaceutical companies ahead for their earnings.
In an interview to CNBC-TV18, Praful Borah of Nirmal Bang Institutional Equities speak about Glenmark, Divi's results and gives his outlook going forward.
Pharmaceutical companies are expected to report healthy 15-25% year-on-year revenue growth in the third quarter, helped by new launches especially in the US and strong demand for generic drugs.
Emkay Global Financial Services has come with its December quarterly earning estimates for pharmaceutical sector. According to the research firm the sector is expected to report a growth of 18% YoY (5% QoQ) in revenues partly driven by Rupee depreciation which is likely to be 4-5% of the overall growth.